Mrs Kathy Jackson
Honorary (Senior Fellow)
Department of Infectious Diseases
19 Scholarly works
1 Projects
HIGHLIGHTS
2025
Journal article
Development and verification of a novel tiling PCR method for long-range HIV-1 sequencing in a diagnostic setting
DOI: 10.1038/s41598-025-03190-62024
Research grants (other domestic)
Development of a Point of Care Assay for the Hepatitis B E Antigen
2024
Journal article
High end-of-treatment hepatitis B core-related antigen levels predict hepatitis flare after stopping nucleot(s)ide analogue therapy
DOI: 10.1111/liv.160292023
Journal article
Laboratory evaluation of ELISA and indirect immunofluorescence assay in response to emergence of Japanese encephalitis virus genotype IV in Australia
DOI: 10.1016/j.jcv.2023.1055802023
Journal article
Baseline serum HBV RNA is associated with the risk of hepatitis flare after stopping nucleoside analog therapy in HBeAg-negative participants
DOI: 10.1097/HC9.00000000000001882023
Journal article
Laboratory assessment of a multi-target assay for the rapid detection of viruses causing vesicular diseases
DOI: 10.1016/j.jcv.2023.1055252023
Journal article
Evaluation of 16 molecular assays for the detection of orthopox and mpox viruses
DOI: 10.1016/j.jcv.2023.105424
RECENT SCHOLARLY WORKS
2023
Journal article
Hepatitis B virus haplotype number at baseline is a predictive marker of functional cure during antiviral therapy for patients with genotypes A and D HBeAg-positive chronic hepatitis B
DOI: 10.1111/apt.172992023
Journal article
Hepatitis B Virus Flares after Nucleot(s)ide Analogue Cessation Are Associated with Activation of Toll-Like Receptor Signaling Pathways
DOI: 10.1093/infdis/jiac3752022
Journal article
Preventing early childhood transmission of hepatitis B in remote aboriginal communities in Northern Australia
DOI: 10.1186/s12939-022-01808-z2022
Journal article
Assessment of the cobas® HBV RNA investigational assay in the setting of nucleoside analog therapy cessation
DOI: 10.1002/jmv.28078